Literature DB >> 18223465

Evaluation and comparison of simple multiple model, richer data multiple model, and sequential interacting multiple model (IMM) Bayesian analyses of gentamicin and vancomycin data collected from patients undergoing cardiothoracic surgery.

Iona Macdonald1, Christine E Staatz, Roger W Jelliffe, Alison H Thomson.   

Abstract

This study compared the abilities of three Bayesian algorithms-simple multiple model (SMM) using a single creatinine measurement; richer data multiple model (RMM) using all creatinine measurements; and the sequential interacting multiple model (IMM)-to describe gentamicin and vancomycin concentration-time data from patients within a cardiothoracic surgery unit who had variable renal function. All algorithms start with multiple sets of discrete parameter support points obtained from nonparametric population modeling. The SMM and RMM Bayesian algorithms then estimate their Bayesian posterior probabilities by conventionally assuming that the estimated parameter distributions are fixed and unchanging throughout the period of data analysis. In contrast, the IMM sequential Bayesian algorithm permits parameter estimates to jump from one population model support point to another, as new data are analyzed, if the probability of a different support point fitting the more recent data is more likely. Several initial IMM jump probability settings were examined-0.0001%, 0.1%, 3%, and 10%-and a probability range of 0.0001% to 50%. The data sets comprised 550 gentamicin concentration measurements from 135 patients and 555 vancomycin concentration measurements from 139 patients. The SMM algorithm performed poorly with both antibiotics. Improved precision was obtained with the RMM algorithm. However, the IMM algorithm fitted the data with the highest precision. A 3% jump probability gave the best estimates. In contrast, the IMM 0.0001% to 50% range setting performed poorly, especially for vancomycin. In summary, the IMM algorithm described and tracked drug concentration data well in these clinically unstable patients. Further investigation of this new approach in routine clinical care and optimal dosage design is warranted.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18223465      PMCID: PMC2724314          DOI: 10.1097/FTD.0b013e318161a38c

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  15 in total

1.  A Bayesian approach to tracking patients having changing pharmacokinetic parameters.

Authors:  David S Bayard; Roger W Jelliffe
Journal:  J Pharmacokinet Pharmacodyn       Date:  2004-02       Impact factor: 2.745

2.  Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies.

Authors:  Aida Bustad; Dimiter Terziivanov; Robert Leary; Ruediger Port; Alan Schumitzky; Roger Jelliffe
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

3.  Prediction of creatinine clearance from serum creatinine.

Authors:  D W Cockcroft; M H Gault
Journal:  Nephron       Date:  1976       Impact factor: 2.847

4.  Population pharmacokinetic modelling of gentamicin and vancomycin in patients with unstable renal function following cardiothoracic surgery.

Authors:  Christine E Staatz; Colette Byrne; Alison H Thomson
Journal:  Br J Clin Pharmacol       Date:  2006-02       Impact factor: 4.335

5.  Pharmacokinetics of gentamicin in 957 patients with varying renal function dosed once daily.

Authors:  C M Kirkpatrick; S B Duffull; E J Begg
Journal:  Br J Clin Pharmacol       Date:  1999-06       Impact factor: 4.335

Review 6.  Model-based, goal-oriented, individualised drug therapy. Linkage of population modelling, new 'multiple model' dosage design, bayesian feedback and individualised target goals.

Authors:  R W Jelliffe; A Schumitzky; D Bayard; M Milman; M Van Guilder; X Wang; F Jiang; X Barbaut; P Maire
Journal:  Clin Pharmacokinet       Date:  1998-01       Impact factor: 6.447

7.  Estimation of creatinine clearance in patients with unstable renal function, without a urine specimen.

Authors:  Roger Jelliffe
Journal:  Am J Nephrol       Date:  2002 Jul-Aug       Impact factor: 3.754

8.  The use of a change in gentamicin clearance as an early predictor of gentamicin-induced nephrotoxicity.

Authors:  Carl M J Kirkpatrick; Stephen B Duffull; Evan J Begg; Chris Frampton
Journal:  Ther Drug Monit       Date:  2003-10       Impact factor: 3.681

9.  Population pharmacokinetics of gentamicin in patients with cancer.

Authors:  M C Rosario; A H Thomson; D I Jodrell; C A Sharp; H L Elliott
Journal:  Br J Clin Pharmacol       Date:  1998-09       Impact factor: 4.335

10.  Pattern of renal dysfunction associated with myocardial revascularization surgery and cardiopulmonary bypass.

Authors:  A Faulí; C Gomar; J M Campistol; L Alvarez; A M Manig; P Matute
Journal:  Eur J Anaesthesiol       Date:  2003-06       Impact factor: 4.330

View more
  10 in total

1.  Challenges in Individualizing Drug Dosage for Intensive Care Unit Patients: Is Augmented Renal Clearance What We Really Want to Know? Some Suggested Management Approaches and Clinical Software Tools.

Authors:  Roger Jelliffe
Journal:  Clin Pharmacokinet       Date:  2016-08       Impact factor: 6.447

Review 2.  Optimising antimicrobial therapy through the use of Bayesian dosing programs.

Authors:  M L Avent; B A Rogers
Journal:  Int J Clin Pharm       Date:  2019-08-07

3.  Author's Reply to Proost: "Challenges in Individualizing Drug Dosage for Intensive Care Unit Patients".

Authors:  Roger W Jelliffe
Journal:  Clin Pharmacokinet       Date:  2017-03       Impact factor: 6.447

4.  Author's reply to Veloso HH Comment on "The Role of Digitalis Pharmacokinetics in Converting Atrial Fibrillation and Flutter to Sinus Rhythm".

Authors:  Roger W Jelliffe
Journal:  Clin Pharmacokinet       Date:  2016-05       Impact factor: 6.447

5.  Comparative Evaluation of the Predictive Performances of Three Different Structural Population Pharmacokinetic Models To Predict Future Voriconazole Concentrations.

Authors:  Andras Farkas; Gergely Daroczi; Phillip Villasurda; Michael Dolton; Midori Nakagaki; Jason A Roberts
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

6.  Population pharmacokinetics of conventional and intermittent dosing of liposomal amphotericin B in adults: a first critical step for rational design of innovative regimens.

Authors:  William W Hope; Joanne Goodwin; Timothy W Felton; Michael Ellis; David A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2012-08-06       Impact factor: 5.191

7.  Software for dosage individualization of voriconazole for immunocompromised patients.

Authors:  William W Hope; Michael Vanguilder; J Peter Donnelly; Nicole M A Blijlevens; Roger J M Brüggemann; Roger W Jelliffe; Michael N Neely
Journal:  Antimicrob Agents Chemother       Date:  2013-02-04       Impact factor: 5.191

8.  Population Pharmacokinetic Modeling of Vancomycin in Thai Patients With Heterogeneous and Unstable Renal Function.

Authors:  Siriluk Jaisue; Cholatip Pongsakul; David Z D'Argenio; Pakawadee Sermsappasuk
Journal:  Ther Drug Monit       Date:  2020-12       Impact factor: 3.118

9.  Tools for the Individualized Therapy of Teicoplanin for Neonates and Children.

Authors:  V Ramos-Martín; M N Neely; K Padmore; M Peak; M W Beresford; M A Turner; S Paulus; J López-Herce; W W Hope
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

10.  A hybrid machine learning/pharmacokinetic approach outperforms maximum a posteriori Bayesian estimation by selectively flattening model priors.

Authors:  Jasmine H Hughes; Ron J Keizer
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2021-07-26
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.